Skip to main content
OpenTrials

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,170 public trials 550 recruiting studies
Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1220.7.0091 Boehringer Ingelheim Investigational Site North Little Rock, Arkansas, United States
  • 1220.7.0082 Boehringer Ingelheim Investigational Site Englewood, Colorado, United States
  • 1220.7.0095 Boehringer Ingelheim Investigational Site Palm Harbor, Florida, United States
  • 1220.7.0039 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States
View all 116 locations
View Trial Details
Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

NCT02753699

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Novartis Investigative Site La Jolla, California, United States
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site Ventura, California, United States
  • Novartis Investigative Site Bradenton, Florida, United States
View all 119 locations
View Trial Details
Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

NCT01277601

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis B, +15 more
Locations
  • Asian Pacific Liver Center Los Angeles, California, United States
  • Stanford University Medical Center Palo Alto, California, United States
  • Research and Education Inc San Diego, California, United States
  • San Jose Gastroenterology San Jose, California, United States
View all 171 locations
View Trial Details
Completed

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site Ventura, California, United States
  • Novartis Investigative Site Bradenton, Florida, United States
View all 75 locations
View Trial Details

Related conditions